Lung Cancer

Latest News

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identified a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced Mesothelioma

March 13th 2023

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer
FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors

February 9th 2023

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.
FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.
Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022

More News